Candel therapeutics announces upcoming presentations at asgct and asco

Needham, mass., may 02, 2023 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced an abstract detailing new data from its phase 1 clinical trial of can-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming american society of gene and cell therapy (asgct) 26th annual meeting in los angeles, ca and virtually, may 16-20, 2023. additionally, the company will present a trials-in-progress poster from its phase 2 clinical trial of can-2409 plus valacyclovir and anti-pd1 antibodies in patients with stage iii/iv non-small cell lung cancer (nsclc) at the 2023 american society of clinical oncology (asco) 27th annual meeting in chicago, il and virtually, june 2-6, 2023.
CADL Ratings Summary
CADL Quant Ranking